Chinese Traditional and Herbal Drugs
|
2025, 56(6): 2122-2134
Research on quality marker of Dendropanax dentiger for treatment of rheumatoid arthritis based on fingerprint -network pharmacology-multi-index quantification
Full
FAN Xinrong1,2, ZHANG Leyi1, LUO Sha3, YUAN Zhouxin1, LI Fan4, XUE Chang2, WANG Huiyu1, JIANG Chengxi2
Affiliations
1 Department of Pharmacy, Lishui Hospital of Traditional Chinese Medicine Affiliated Hospital of Zhejiang Chinese Medical University, Lishui 323000, China;
2 School of Pharmacy, Wenzhou Medical University, Wenzhou 325035, China;
3 School of Health Sciences, Chongqing Vocational Institute of Engineering, Chongqing 400000, China;
4 Zhejiang Jolly Pharmaceutical Co., Ltd., Huzhou 313000, China
doi: 10.7501/j.issn.0253-2670.2025.06.024
Outline
Objective To analyze and predict the differential active components of Dendropanax dentiger using fingerprint and network pharmacology methods, establish quantitative analysis methods, and provide a reference for the quality control of D. dentiger. Methods High-performance liquid chromatography (HPLC) was used to establish the fingerprint of D. dentiger, and chemometric analysis was employed to screen the main differential components from different origins. Furthermore, network pharmacology was applied to identify the core targets and key pathways of the characteristic components of D. dentiger in the treatment of rheumatoid arthritis (RA). A “component-core target-pathway” network was constructed to predict the differential active components of D. dentiger for anti-RA effects. The content of the differential active components was determined in 28 batches of D. dentiger samples, and the final differential active components were identified. Results The HPLC fingerprint of 28 batches of D. dentiger samples was established, with 13 common peaks identified, including 5 peaks assigned as protocatechuic acid, syringin, chlorogenic acid, isochlorogenic acid A, and isochlorogenic acid C. Chemometric analysis preliminarily identified syringin, chlorogenic acid, isochlorogenic acid A, and isochlorogenic acid C as the main differential components. Network pharmacology analysis revealed that syringin, chlorogenic acid, isochlorogenic acid A, and isochlorogenic acid C might exert therapeutic effects on RA through 8 core targets, including prostaglandin-endoperoxide synthase 2 (PTGS2), caspase 3 (CASP3), epidermal growth factor receptor (EGFR), matrix metalloproteinase-2 (MMP2), matrix metalloproteinase-3 (MMP3), E-selectin (SELE), P-selectin (SELP), and prostaglandin-endoperoxide synthase 1 (PTGS1), influencing signaling pathways such as lipid and atherosclerosis, renin-angiotensin system, interleukin-17 (IL-17), and tumor necrosis factor (TNF). Finally, syringin, chlorogenic acid, isochlorogenic acid A, and isochlorogenic acid C were determined as the differential active components of D. dentiger for the treatment of RA. Conclusion The established quality evaluation method is accurate and reliable. The differential active components screened by network pharmacology provide a basis for the quality control of D. dentiger and insights into its mechanism of action in treating RA.
Dendropanax dentiger (Harms) Merr.
/
differential active components
/
quality marker
/
fingerprint
/
network pharmacology
/
multi-component quantification
/
gallic acid
/
syringin
/
chlorogenic acid
/
isochlorogenic acid A
/
isochlorogenic acid C
范欣荣, 张乐怡, 罗莎, 袁宙新, 李帆, 薛畅, 王慧玉, 姜程曦.
基于指纹图谱-网络药理学-多指标定量分析预测树参中的差异活性成分.
中草药,
2025
, 56
(6)
: 2122
-2134
.
DOI: 10.7501/j.issn.0253-2670.2025.06.024
FAN Xinrong, ZHANG Leyi, LUO Sha, YUAN Zhouxin, LI Fan, XUE Chang, WANG Huiyu, JIANG Chengxi.
Research on quality marker of Dendropanax dentiger for treatment of rheumatoid arthritis based on fingerprint -network pharmacology-multi-index quantification[J].
Chinese Traditional and Herbal Drugs,
2025
, 56
(6)
: 2122
-2134
.
DOI: 10.7501/j.issn.0253-2670.2025.06.024
Year 2025 volume 56 Issue 6
47
7
Cite this Article
BibTeX
Article Info
doi: 10.7501/j.issn.0253-2670.2025.06.024
- Receive Date:2024-10-05
- Online Date:2026-11-13